Business
Sequana Medical announces results of Annual General Meeting of Shareholders
Ghent, Belgium, May 28, 2026 (GLOBE NEWSWIRE) -- PRESS RELEASE | REGULATED INFORMATION | 28 May 2026, 9:00 pm CEST Ghent, Belgium – 28 May 2026 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today the results of the Annual General Meeting of Shareholders (the "AGM") held today at 09:00 am CEST, at which the treatment of certain agenda items was
About this update from Sequana Medical N.v
[{"type":"image","alt":"Sequana Medical NV","displaySize":"","headline":null,"caption":"Sequana Medical NV","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":64,"url":"https://media.zenfs.com/en/globenewswire.com/eebd983759ebc3a966954513471e9960"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZrIpOehiKz_M4rbjFpbY5A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkw/https://media.zenfs.com/en/globenewswire.com/eebd983759ebc3a966954513471e9960","width":300,"height":64},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/ZrIpOehiKz_M4rbjFpbY5A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkw/https://media.zenfs.com/en/globenewswire.com/eebd983759ebc3a966954513471e9960","width":300,"height":64}},"lazy":false},{"type":"text","content":"Ghent, Belgium, May 28, 2026 (GLOBE NEWSWIRE) -- PRESS RELEASE | REGULATED INFORMATION | 28 May 2026, 9:00 pm CEST","length":114,"tagName":"p"},{"type":"text","content":"Ghent, Belgium – 28 May 2026 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today the results of the Annual General Meeting of Shareholders (the "AGM") held today at 09:00 am CEST, at which the treatment of certain agenda items was adjourned and all remaining agenda items submitted to a vote were approved.","length":490,"tagName":"p"},{"type":"text","content":"As previously announced on 28 April 2026, the Company is conducting a review of a range of financial and strategic options to address its current financial position and the future of its business. This review may include, among other things, financing transactions, a strategic or corporate transaction (involving the Company or its assets), or other measures. At this stage, several options are being reviewed, but no decision has been taken, and there can be no assurance as to whether any final option will be available or whether any measures will be implemented, nor as to their outcome or timing. This review is still ongoing. Against this background, the Company's statutory and consolidated financial statements for the financial year ended 31 December 2025, together with the related reports of the board of directors and the statutory auditor, were not yet available at the time of the AGM.","length":904,"...